These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 21170936)
1. Butein, a tetrahydroxychalcone, suppresses cancer-induced osteoclastogenesis through inhibition of receptor activator of nuclear factor-kappaB ligand signaling. Sung B; Cho SG; Liu M; Aggarwal BB Int J Cancer; 2011 Nov; 129(9):2062-72. PubMed ID: 21170936 [TBL] [Abstract][Full Text] [Related]
2. Guggulsterone inhibits osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand and by tumor cells by suppressing nuclear factor-kappaB activation. Ichikawa H; Aggarwal BB Clin Cancer Res; 2006 Jan; 12(2):662-8. PubMed ID: 16428513 [TBL] [Abstract][Full Text] [Related]
4. Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand through modulation of NF-kappaB pathway. Ahn KS; Sethi G; Chaturvedi MM; Aggarwal BB Int J Cancer; 2008 Oct; 123(8):1733-40. PubMed ID: 18688862 [TBL] [Abstract][Full Text] [Related]
5. Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis. Bharti AC; Takada Y; Aggarwal BB J Immunol; 2004 May; 172(10):5940-7. PubMed ID: 15128775 [TBL] [Abstract][Full Text] [Related]
6. Triptolide, a diterpene, inhibits osteoclastogenesis, induced by RANKL signaling and human cancer cells. Park B Biochimie; 2014 Oct; 105():129-36. PubMed ID: 25047443 [TBL] [Abstract][Full Text] [Related]
7. Embelin suppresses osteoclastogenesis induced by receptor activator of NF-κB ligand and tumor cells in vitro through inhibition of the NF-κB cell signaling pathway. Reuter S; Prasad S; Phromnoi K; Kannappan R; Yadav VR; Aggarwal BB Mol Cancer Res; 2010 Oct; 8(10):1425-36. PubMed ID: 20826545 [TBL] [Abstract][Full Text] [Related]
8. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways. Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972 [TBL] [Abstract][Full Text] [Related]
9. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo. Zhu L; Wei H; Wu Y; Yang S; Xiao L; Zhang J; Peng B Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613 [TBL] [Abstract][Full Text] [Related]
10. Calebin A downregulates osteoclastogenesis through suppression of RANKL signalling. Tyagi AK; Prasad S; Majeed M; Aggarwal BB Arch Biochem Biophys; 2016 Mar; 593():80-9. PubMed ID: 26874195 [TBL] [Abstract][Full Text] [Related]
11. 1'-Acetoxychavicol acetate inhibits RANKL-induced osteoclastic differentiation of RAW 264.7 monocytic cells by suppressing nuclear factor-kappaB activation. Ichikawa H; Murakami A; Aggarwal BB Mol Cancer Res; 2006 Apr; 4(4):275-81. PubMed ID: 16603641 [TBL] [Abstract][Full Text] [Related]
13. Resveratrol-mediated SIRT-1 interactions with p300 modulate receptor activator of NF-kappaB ligand (RANKL) activation of NF-kappaB signaling and inhibit osteoclastogenesis in bone-derived cells. Shakibaei M; Buhrmann C; Mobasheri A J Biol Chem; 2011 Apr; 286(13):11492-505. PubMed ID: 21239502 [TBL] [Abstract][Full Text] [Related]
14. Thiocolchicoside suppresses osteoclastogenesis induced by RANKL and cancer cells through inhibition of inflammatory pathways: a new use for an old drug. Reuter S; Gupta SC; Phromnoi K; Aggarwal BB Br J Pharmacol; 2012 Apr; 165(7):2127-39. PubMed ID: 21955206 [TBL] [Abstract][Full Text] [Related]
15. Zerumbone abolishes RANKL-induced NF-kappaB activation, inhibits osteoclastogenesis, and suppresses human breast cancer-induced bone loss in athymic nude mice. Sung B; Murakami A; Oyajobi BO; Aggarwal BB Cancer Res; 2009 Feb; 69(4):1477-84. PubMed ID: 19190327 [TBL] [Abstract][Full Text] [Related]
16. Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signaling. Sung B; Oyajobi B; Aggarwal BB Mol Cancer Ther; 2012 Feb; 11(2):350-9. PubMed ID: 22090419 [TBL] [Abstract][Full Text] [Related]
17. Shikimic Acid Inhibits Osteoclastogenesis in Vivo and in Vitro by Blocking RANK/TRAF6 Association and Suppressing NF-κB and MAPK Signaling Pathways. Chen X; Li X; Zhai X; Zhi X; Cao L; Qin L; Su J Cell Physiol Biochem; 2018; 51(6):2858-2871. PubMed ID: 30562759 [TBL] [Abstract][Full Text] [Related]
18. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways. Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1. Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185 [TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis. Kimachi K; Kajiya H; Nakayama S; Ikebe T; Okabe K Naunyn Schmiedebergs Arch Pharmacol; 2011 Mar; 383(3):297-308. PubMed ID: 21225243 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]